Biora Therapeutics announces preliminary results from PGN-OB1 program

Biora Therapeutics announced preliminary results from preclinical testing of its PGN-OB1 program, reporting an average bioavailability greater than 50% for a variant of adalimumab. "To achieve this level of oral bioavailability with an over 50 mg dose of a monoclonal antibody similar to Humira represents an important and significant development step forward in our program for oral delivery of biologics," said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. "As previously shared, we have been working on a next-generation device for our systemic delivery platform and we were looking to achieve at least the same level of performance as our previous generation device. We are thrilled with the results to date, which not only surpassed our previous average bioavailability of 25% in animal models, but also exceeded our expectations in regard to the consistency of the data," continued Mr. Mohanty. "Our work continues toward finalizing this next-generation autonomous device for preclinical use over the coming months, which we anticipate will enable us to progress our pharma collaboration opportunities and help us achieve our partnering goals this year."